1
|
Oti VB, Idris A, McMillan NAJ. Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape. Expert Rev Anti Infect Ther 2024:1-11. [PMID: 38973346 DOI: 10.1080/14787210.2024.2378185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2023] [Accepted: 07/05/2024] [Indexed: 07/09/2024]
Abstract
INTRODUCTION Respiratory syncytial virus (RSV) causes bronchiolitis and other respiratory issues in immunocompromised individuals, the elderly, and children. After six decades of research, we have only recently seen the approval of two RSV vaccines, Arexvy and Abrysvo. Direct-acting antivirals against RSV have been more difficult to develop with ribavirin and palivizumab giving very modest reductions in hospitalizations and no differences in mortality. Recently, nirsevimab was licensed and has proven to be much more effective when given prophylactically. These are delivered intravenously (IV) and intramuscularly (IM), but an intranasal (IN) antiviral has several advantages in terms of ease of use, lower resource need, and acting at the site of infection. AREAS COVERED In this paper, we review the available literature on the current pre-clinical research landscape of anti-RSV therapeutics tested for IN delivery. EXPERT OPINION As RSV is a respiratory virus that infects both the upper and lower respiratory tracts, efforts are focused on developing a therapeutic that can be delivered via the nasal route. The rationale is to directly target the replicating virus with an obvious respiratory tract tropism. This approach will not only pave the way for a nasal delivery approach aimed at reducing respiratory viral illness but also controlling aerosol virus transmission.
Collapse
Affiliation(s)
- Victor Baba Oti
- Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia
- School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia
| | - Adi Idris
- Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Queensland, Australia
| | - Nigel A J McMillan
- Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia
- School of Pharmacy and Medical Sciences, Griffith University, Southport, Queensland, Australia
| |
Collapse
|
2
|
Tan P, Lu L, Wang S, Wang J, Chen J, Zhang Y, Xie L, Yang S, Chen J, Zhang Z. Photo- or Electrochemical Cyclization of Dienes with Diselenides to Access Seleno-Benzo[ b]azepines. J Org Chem 2023. [PMID: 37220067 DOI: 10.1021/acs.joc.3c00475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
A cascade selenylation/cyclization of dienes with diselenides has been realized under visible-light irradiation or electrolysis conditions. Employing O2 or electricity as a "green" oxidant, this protocol provides a green and efficient method for an array of biologically important seleno-benzo[b]azepine derivatives in moderate to good yields. The direct sunlight irradiation and gram-scale reaction render the approach practical and attractive.
Collapse
Affiliation(s)
- Pengpeng Tan
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Liwang Lu
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Shilong Wang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Junxin Wang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Jiayang Chen
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Yijia Zhang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Lei Xie
- School of Pharmaceutical Sciences, Liaocheng University, Liaocheng 252000, P. R. China
| | - Shubin Yang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Jinchun Chen
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| | - Zhen Zhang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, P. R. China
| |
Collapse
|
3
|
Zhang Z, Wang S, Tan P, Gu X, Sun W, Liu C, Chen J, Li J, Sun K. K 2S 2O 8/I 2-Promoted Electrophilic Selenylative Cyclization To Access Seleno-Benzo[ b]azepines. Org Lett 2022; 24:2288-2293. [PMID: 35319211 DOI: 10.1021/acs.orglett.2c00387] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel and simple organoselenium-involved 7-membered cyclization to access diverse seleno-benzo[b]azepines has been developed. This protocol involves an electrophilic cyclization process and is accomplished under mild conditions. Discussion of the mechanism rationalizes the regioselectivity observed in transformation. The studies of further transformation of seleno-benzo[b]azepines and large-scale experiment reveal the promising utility of this methodology.
Collapse
Affiliation(s)
- Zhen Zhang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Shilong Wang
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Pengpeng Tan
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Xiaowen Gu
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Wenjie Sun
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Chang Liu
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Jinchun Chen
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Jiazhu Li
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| | - Kai Sun
- College of Chemistry and Chemical Engineering, Yantai University, Yantai, 264005, P. R. China
| |
Collapse
|
4
|
An Z, Ren Y, Liu Y, Yan R. I 2 -Promoted Intramolecular Oxidative Cyclization of Butenyl Anilines: A Facile Route to Benzo[b]azepines. Chem Asian J 2021; 16:2614-2617. [PMID: 34342932 DOI: 10.1002/asia.202100710] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 07/11/2021] [Indexed: 12/16/2022]
Abstract
A metal-free approach for the synthesis of seven-membered N-heterocycles has been developed by the I2 -promoted intramolecular cross-coupling/annulation of butenyl anilines. This cyclization reaction involves C-H activation and C-C bond formation and exhibits good functional group tolerance. A series of benzo[b]azepine derivatives are obtained in moderate to good yields.
Collapse
Affiliation(s)
- Zhenyu An
- State Key Laboratory of Applied Organic Chemistry, Key laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China
| | - Yi Ren
- State Key Laboratory of Applied Organic Chemistry, Key laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China
| | - Yafeng Liu
- Chemical Science and Engineering College, North Minzu University, Yinchuan, 750000, P. R. China
| | - Rulong Yan
- State Key Laboratory of Applied Organic Chemistry, Key laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, P. R. China
| |
Collapse
|
5
|
Liao Y, Ye Z, Qian M, Wang X, Guo Y, Han G, Song Y, Hou J, Liu Y. Photoactive NO hybrids with pseudo-zero-order release kinetics for antimicrobial applications. Org Biomol Chem 2021; 18:5473-5480. [PMID: 32643744 DOI: 10.1039/d0ob00564a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Bacterial infection is a major threat to the health and life of humans due to the development of drug resistance, which is related to biofilm formation. Nitric oxide (NO) has emerged as an important factor in regulating biofilm formation. In order to harness the potential benefits of NO and develop effective antibacterial agents, we designed and synthesized a new class of NO hybrids in which the active scaffold benzothienoazepine was tagged with a nitroso group and further conjugated with quaternary ammoniums or phosphoniums. The temporal release of NO from these hybrids can be achieved by photoactivation. Interestingly, the NO release follows a pseudo-zero-order kinetics, which is easily determined by measuring the fluorescent benzothienoazepine or NO. Compared to the positive control ciprofloxacin, the NO hybrid with triphenyl phosphonium (TPP) exhibited more effective activity against S. aureus biofilm in darkness. Irradiation of the NO hybrid led to higher inhibition against S. aureus biofilm compared to the parental NO hybrid in darkness or the corresponding NO-released product, indicating the combined effect of NO and the NO-released product. Therefore, this new class of NO hybrids includes very promising antimicrobial agents and this work provides a new way for the design of highly effective antimicrobial agents.
Collapse
Affiliation(s)
- Yongfang Liao
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Zizhen Ye
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Meng Qian
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Xing Wang
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Yuda Guo
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Guifang Han
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Yuguang Song
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Jingli Hou
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| | - Yangping Liu
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, P. R. China.
| |
Collapse
|
6
|
Xu J, Wu W, Chen H, Xue Y, Bao X, Zhou J. Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses. Bioorg Med Chem 2021; 39:116157. [PMID: 33895704 DOI: 10.1016/j.bmc.2021.116157] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2020] [Revised: 03/25/2021] [Accepted: 03/30/2021] [Indexed: 12/12/2022]
Abstract
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children, and specific treatment for RSV infections remains unavailable. We herein reported a series of substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent RSV inhibitors. Among them, six low cytotoxic compounds (11, 12, 15, 22, 26, and 28) have been identified and selected to study associated inhibitory mechanisms. All these compounds suppressed not only the viral replication but also RSV-induced IRF3 and NF-κB activation and associated production of cytokines/chemokines. The two most potent compounds (15 and 22) were selected for further molecular mechanism studies associated with their suppression effect on RSV-activated IRF3 and NF-κB. These two compounds decreased RSV-induced IRF3 phosphorylation at serine 396 and p65 phosphorylation at serine 536 at both early and late infection phases. In addition, compound 22 also inhibited RSV-induced p65 phosphorylation at serine 276 at the late phase of RSV infection.
Collapse
Affiliation(s)
- Jimin Xu
- Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States
| | - Wenzhe Wu
- Department of Pediatrics, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States
| | - Haiying Chen
- Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States
| | - Yu Xue
- Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States
| | - Xiaoyong Bao
- Department of Pediatrics, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States; Sealy Center for Molecular Medicine, and University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States; Institute for Human Infections and Immunity, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States.
| | - Jia Zhou
- Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States; Sealy Center for Molecular Medicine, and University of Texas Medical Branch (UTMB), Galveston, TX 77555, United States.
| |
Collapse
|
7
|
Discovery of a Novel Respiratory Syncytial Virus Replication Inhibitor. Antimicrob Agents Chemother 2021; 65:AAC.02576-20. [PMID: 33782012 PMCID: PMC8316115 DOI: 10.1128/aac.02576-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 02/18/2021] [Indexed: 11/20/2022] Open
Abstract
A high-throughput screen of a Roche internal chemical library based on inhibition of the respiratory syncytial virus (RSV)-induced cytopathic effect (CPE) on HEp-2 cells was performed to identify RSV inhibitors. Over 2,000 hits were identified and confirmed to be efficacious against RSV infection in vitro Here, we report the discovery of a triazole-oxadiazole derivative, designated triazole-1, as an RSV replication inhibitor, and we characterize its mechanism of action. Triazole-1 inhibited the replication of both RSV A and B subtypes with 50% inhibitory concentration (IC50) values of approximately 1 μM, but it was not effective against other viruses, including influenza virus A, human enterovirus 71 (EV71), and vaccinia virus. Triazole-1 was shown to inhibit RSV replication when added at up to 8 h after viral entry, suggesting that it inhibits RSV after viral entry. In a minigenome reporter assay in which RSV transcription regulatory sequences flanking a luciferase gene were cotransfected with RSV N/P/L/M2-1 genes into HEp-2 cells, triazole-1 demonstrated specific and dose-dependent RSV transcription inhibitory effects. Consistent with these findings, deep sequencing of the genomes of triazole-1-resistant mutants revealed a single point mutation (A to G) at nucleotide 13546 of the RSV genome, leading to a T-to-A change at amino acid position 1684 of the L protein, which is the RSV RNA polymerase for both viral transcription and replication. The effect of triazole-1 on minigenome transcription, which was mediated by the L protein containing the T1684A mutation, was significantly reduced, suggesting that the T1684A mutation alone conferred viral resistance to triazole-1.
Collapse
|
8
|
Bergeron HC, Tripp RA. Emerging small and large molecule therapeutics for respiratory syncytial virus. Expert Opin Investig Drugs 2020; 29:285-294. [PMID: 32096420 DOI: 10.1080/13543784.2020.1735349] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Introduction: Respiratory syncytial virus (RSV) causes lower respiratory tract infections and can lead to morbidity and mortality in the infant, elderly and immunocompromised. There is no vaccine and therapeutic interventions are limited. RSV disease research has yielded the development of several prophylactic and therapeutic treatments. Several promising candidates are currently under investigation.Areas covered: Small and large molecule approaches to RSV treatment were examined and categorized by their mechanism of action using data from PubMed, clinicaltrials.gov, and from the sponsoring organizations publicly available pipeline information. These results are prefaced by an overview of RSV to provide the context for rational therapy development.Expert opinion: While small molecule drugs show promise for RSV treatment, we believe that large molecule therapy using anti-RSV G and F protein monoclonal antibodies (mAbs) will most efficaciously and safely ameliorate RSV disease.
Collapse
Affiliation(s)
- Harrison C Bergeron
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| | - Ralph A Tripp
- Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, USA
| |
Collapse
|
9
|
Dubois MAJ, Lazaridou A, Choi C, Mousseau JJ, Bull JA. Synthesis of 3-Aryl-3-Sulfanyl Azetidines by Iron-Catalyzed Thiol Alkylation with N-Cbz Azetidinols. J Org Chem 2019; 84:5943-5956. [PMID: 30973723 DOI: 10.1021/acs.joc.9b00613] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
New small-ring derivatives can provide valuable motifs in new chemical space for drug design. 3-Aryl-3-sulfanyl azetidines are synthesized directly from azetidine-3-ols in excellent yield by a mild Fe-catalyzed thiol alkylation. A broad range of thiols and azetidinols bearing electron-donating aromatics are successful, proceeding via an azetidine carbocation. The N-carboxybenzyl group is a requirement for good reactivity and enables the NH-azetidine to be revealed. Further reactions of the azetidine sulfides demonstrate their potential for incorporation in drug discovery programs.
Collapse
Affiliation(s)
- Maryne A J Dubois
- Department of Chemistry , Imperial College London, Molecular Sciences Research Hub, White City Campus , Wood Lane , London W12 0BZ , U.K
| | - Anna Lazaridou
- Department of Chemistry , Imperial College London, Molecular Sciences Research Hub, White City Campus , Wood Lane , London W12 0BZ , U.K
| | - Chulho Choi
- Pfizer Medicinal Sciences , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - James J Mousseau
- Pfizer Medicinal Sciences , 445 Eastern Point Road , Groton , Connecticut 06340 , United States
| | - James A Bull
- Department of Chemistry , Imperial College London, Molecular Sciences Research Hub, White City Campus , Wood Lane , London W12 0BZ , U.K
| |
Collapse
|
10
|
Cockerill GS, Good JAD, Mathews N. State of the Art in Respiratory Syncytial Virus Drug Discovery and Development. J Med Chem 2018; 62:3206-3227. [DOI: 10.1021/acs.jmedchem.8b01361] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- G. Stuart Cockerill
- ReViral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom
| | - James A. D. Good
- ReViral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom
| | - Neil Mathews
- ReViral Ltd., Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2FX, United Kingdom
| |
Collapse
|
11
|
Mantero M, Rogliani P, Cazzola M, Blasi F, Di Pasquale M. Emerging antibacterial and antiviral drugs for treating respiratory tract infections. Expert Opin Emerg Drugs 2018; 23:185-199. [DOI: 10.1080/14728214.2018.1504020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Marco Mantero
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center,IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Paola Rogliani
- Respiratory Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Mario Cazzola
- Respiratory Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy
| | - Francesco Blasi
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center,IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - Marta Di Pasquale
- Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Internal Medicine Department, Respiratory Unit and Regional Adult Cystic Fibrosis Center,IRCCS Fondazione Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
| |
Collapse
|
12
|
Fordyce EAF, Fraser Hunt S, Crepin D, Onions ST, Parra GF, Sleigh CJ, King-Underwood J, Finch H, Murray J. Conformationally restricted benzothienoazepine respiratory syncytial virus inhibitors: their synthesis, structural analysis and biological activities. MEDCHEMCOMM 2018; 9:583-589. [PMID: 30108949 DOI: 10.1039/c8md00033f] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 02/16/2018] [Indexed: 11/21/2022]
Abstract
Atropisomeric drug substances are known to have different biological properties. Compounds containing the N-benzoylbenzazepine motif have been shown to exhibit energetically restricted rotation around the Ar(CO)N axis. Herein we report, for the first time, the synthesis, physical characterisation and anti-viral profiles of a series of C-4 and C-5 methylated thieno-benzazepines. NMR analysis reveals that incorporation of a single additional substituent at either of these loci influences the conformational dynamics of the azepine ring system. In the case of the C-5 alkyl analogues, the influence of the new stereocentre is so pronounced that its absolute configuration determines which unique atropisomer is obtained following the generation of the benzazepine nucleus. Screening of the alkylated derivatives for their anti-respiratory syncytial virus (RSV) activity indicates that the desired viral pathogenicity is strongly associated with the conformation adopted by the modified tricyclic scaffolds. This is particularly evident in the case of the C-5 homologues in which one atropisomer was found to be potently active and the other essentially inert. These results provide compelling evidence that we have determined the bioactive conformation shared by RSV inhibitors that employ the thienobenazapine nucleus as their core molecular architecture. Furthermore, the understanding obtained from these studies may make it possible to design improved agents against RSV infection in the future.
Collapse
Affiliation(s)
- Euan A F Fordyce
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - S Fraser Hunt
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - Damien Crepin
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - Stuart T Onions
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - Guillaume F Parra
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - Chris J Sleigh
- Sygnature Discovery Ltd. , BioCity , Nottingham , NG1 1GF , UK . ; Tel: +44 (0)1159415401
| | - John King-Underwood
- CompChem Resource , Old Cottage Hospital , Homend , Ledbury , Herefordshire HR8 1ED , UK
| | - Harry Finch
- Pulmocide Ltd. , 52 Princes Gate, Exhibition Road, South Kensington , London , SW7 2PG , UK . ; Tel: +44 (0)2037639484
| | - John Murray
- Pulmocide Ltd. , 52 Princes Gate, Exhibition Road, South Kensington , London , SW7 2PG , UK . ; Tel: +44 (0)2037639484
| |
Collapse
|